Thursday, June 25, 2015

Market Forecast and Opportunities - China Soil Treatment Industry to 2019

·         Future Growth of China Soil Treatment is expected to be led by expansion of cropland and desertion, and advent of Eco-Friendly products
·         The market leader, Syngenta and Wynca Chemical is expected to maintain focus on new product formulants and environment friendly products to compete with other players in the industry

Ken Research announced its latest publication on “China Soil Treatment Market Outlook to 2019” which provides a comprehensive analysis of the various aspects such as market size of the China Organic Amendments Market, Weed Controller market, pH Adjusters market and Pest Controllers Market. The report also covers the market shares of major manufacturers of Soil treatment products as well as the revenues of Weed Controller products.

China Soil Treatment Market
The major sources of Soil pollution in China are industrial waste percolating from factories into the soil, wide application of fertilizers for crop protection and utilization of polluted water for irrigation. The major contaminants that harm the soil of China are Nickel, Arsenic, Lead and Cadmium and others. The majorly affected regions of the country are the industrial regions along the eastern coast and inland provinces in Central and Western regions of the country. Soil Pollution in China has further enhanced local cancer epidemics in the country. Around 450 villages in the country have been recorded to suffer from cancer in 2014. China has around 80 sewage plants that produce approximately 400 million tons of sludge in the country. Lack of public awareness with respect to soil pollution in the country has led to the decline in the expenditure of Soil Pollution in China by the Chinese Government.

China Soil treatment market has witnessed phenomenal growth of ~% from 2009-2014 backed by strong production of weed controllers and organic amendments market. Its steady growth is likely to  be driven by introduction of various innovative formulations, rising industrial pollution in China, dearth of branded players in Organic amendments and pH adjusters market, rising personal disposable income coupled with rise in consumption or organic food. The Soil Treatment market of China is comprised of large companies such as Syngenta, Zhejiang Wynca Chemicals, BASF that posses a large product portfolio of pest and weed Controller products.

According to the research report, the China Soil Treatment market will grow at a considerable CAGR rate thus exceeding 14 billion tons by 2019 due to rising export demand of various herbicides formulations from African and Asian countries.

 “Ban on the production of Methyl Bromide and commencement of new schemes and polices will drive the growth of the segment. While lack of science and technology, feeble public awareness and curtailed government regulations on pesticides are few of the major challenges which will affect the growth of this industry in the future”, according to the Research Associate, Ken Research.

Key Topics Covered in the Report:
Dairy Products
-          Market Size by Production
-          Market Segmentation by
o   Generic and Patented products
o   Organized and Unorganized market
o   By Types of Products
-          Market Segmentation by Organic Amendments Market – Animal Manure, Sewage Sludge, Crop Residue
-          Market Segmentation by Weed Controllers- Glyphosate, Acetochlor, Atrazine, 1,3-Dichloropropne
-          Market Segmentation by pH Adjusters – Aglime and Gypsum
-          Market Segmentation by Pest Controllers – Chloropicrin, Metam- Na( Sodium), Metam - K (Potassium),  1,3-Dichloropropene
-          Trends and Development
-          SWOT
-          Export and Import
-          Competition and Market Share
-          Growth Drivers
-          Future Outlook
-          Macro Economic Parameters

Key Products Mentioned in the Report
Organic Amendments Market (Animal Manure, Sewage Sludge, Crop Residue)
Weed Controllers (Glyphosate, Acetochlor, Atrazine, 1, 3-Dichloropropne)
pH Adjusters (Aglime and Gypsum)
Pest Controllers (Chloropicrin, Metam- Na (Sodium), Metam - K (Potassium), 1, 3-Dichloropropene)

Companies Covered in the Report
Syngenta
BASF
DuPont
Zhejiang Xinan Chemical Industrial Group
Shandong Weifang Rainbow Chemicals
Jiangsu Yangong Chemical Group
Nantong Jiangshan Agrochemical & Chemicals

Related Reports:



Contact:                                                                                                                  
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249

Wednesday, June 24, 2015

Asia Pacific Athletic Apparel and Footwear Market Outlook to 2019 - Surging Growth with Online Marketplaces

·         Future Growth of Athletic Apparel and Footwear Products is expected to be led by China and India athletic apparel and footwear markets
·         The global leaders operating in the industry are expected to maintain focus on enhancing product innovation and marketing strategies to compete with other players in the industry

Ken Research announced its latest publication on “Asia Pacific Athletic Appareland Footwear Market Outlook to 2019” which provides a comprehensive analysis of the athletic apparel and footwear products in China, Japan, Australia and India. The report covers various aspects such as market size of athletic wear, segmentation on the basis of athletic apparel and footwear and geography, and volume of exports and imports for footwear products. The report is useful for athletic apparel and footwear manufacturers, wholesalers, retail chain, consultants and new players venturing in the market.

Athletic apparel and footwear market
The athletic apparel and footwear market in the Asia Pacific region has witnessed a growth in recent years on account of rising health consciousness and increasing sports participation of people of all age groups. The surge in growth has majorly originated from sports participation. Moreover, factors such as increasing awareness about healthy lifestyle, evolution of sports from an entertainment activity to important fitness activity and the trend of wearing sports apparel and regular clothing have contributed significantly towards the expansion of this industry.

The Athletic Apparel and Footwear market in Asia-Pacific has been comprised of multinational companies such as Adidas, Nike and Puma as well as several domestic players which posses a large product portfolio of athletic apparel and footwear products. The Asia Pacific Athletic Apparel and Footwear market revenues have grown at a CAGR of 13% from 2009-2014.

According to the research report, the Asia Pacific Athletic Apparel and Footwear market will grow at a considerable CAGR rate thus exceeding USD 101.1 billion by 2019 due to the increasing sports participation and fashion consciousness of consumers.

“While the rising standards of living, higher disposable incomes, and greater indulgence in outdoor activities will push the athletic apparel and footwear in Asia-Pacific region in the future, weak economic outlook and declining population in Japan are few of the major challenges which will affect the growth of this industry in the future”, according to the Research Analyst, Ken Research.



Key Topics Covered in the Report:
Asia Athletic Apparel and Footwear Market
-          Market Size by Value
-          Market Segmentation by
o   Athletic Apparel and Footwear
o   Geography (China, Japan, Australia, India and Others)
-          Country wise Market Size and Segmentation
-          Competition and Market Share in Major Geographies
-          Trends and Development
-          Future Outlook
-          Analyst Recommendations
-          Macro Economic Parameters

Key Products Mentioned in the Report
Athletic Apparel
Athletic Footwear
Training Wear
Cross Training shoes
Running and jogging shoes
Basketball shoes
Skating shoes
Indoor sportswear
Training wear
Golf wear
Outdoor wear
Soccer wear
Lifestyle wear
Baseball wear
Tennis wear
Fitness wear
Companies Covered in the Report
Nike
Adidas Group
Puma S.E
Anta Sports Products Limited
Li-Ning
361 Degrees International
Xtep International Ltd.
Kappa
Asics
Mizuno
Descente
Goldwin Inc.
Rebel Sports Limited
Amart All Sports
Lorna Jane
Bata
Liberty Shoes Limited
Action Shoes

Related Reports:



Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249

Tuesday, June 16, 2015

India Fitness Services and Equipment Market Future Development

India Fitness Services and Equipment Industry Outlook to 2019 - Increasing Obesity and Disposable Income to Spur Future Growth presents a comprehensive analysis of fitness services and equipments being used in the country by revenue along with the market segmentation by pricing, organizational structure, city-wise concentration for fitness services and by end users, type of equipments, origin for the fitness equipments, growth drivers, and competitive scenario of major players in the India Fitness Services and Equipment Market.


The fitness services and equipment market in India has low penetration and has ample scope for growth in the future. The growth in the India Fitness Services and Equipment Market has been largely impelled by the augmenting demand for fitness services on account of rising lifestyle diseases and obesity. Increasing demand for fitness services and equipments, as contributed by the factors such as high population growth, rising disposable incomes and increasing youth population in India is anticipated to further stimulate the country’s overall fitness services and equipment market in the following years.

Key Topics Covered in the Report:

  • The market size of India Fitness Services and Equipment market in terms of revenue 
  • Consumer profile in the India Fitness Services and Equipment market.
  • India fitness services market segmentation by organizational structure, subscription charges and major cities.
  • India fitness equipment market segmentation by end users on the basis of institutional users and home users; type of fitness on the basis of cardiovascular and strength training and by origin of the fitness equipments.
  • Export and Import Trade in India Fitness Equipment Market
  • Trends and development in the India Fitness Services and Equipment market.
  • SWOT analysis and Porter’s five forces analysis in the India Fitness Services and Equipment Market.
  • Government regulations and growth drivers in India Fitness Services and Equipment market
  • Competitive landscape and consumer profile of major fitness services and equipment players in India.
  • Future outlook and projections of fitness services and equipments in India..
  • Macro economic variables of India Fitness Services and Equipment Market.


Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249

Asia Oncology Drug Market Outlook to 2019 - Market Research Report

·         Future Growth of oncology drug market is expected to be led by countries such as India, China and others
·         The market leader, Roche is expected to maintain focus on Emerging Markets and global brands to compete with other players in the industry.

Ken Research announced its latest publication on “Asia Oncology Drug Market Outlook to 2019 – Rise in Cancer incidences and Ageing Population to Drive the Demand” which provides a comprehensive analysis of the oncology drug market in Asia. The report covers various aspects such as market size of Asia oncology market, segmentation on the basis of type of modalities, treatment, global and local players, and type of cancer. The report also covers India as well as China oncology drug market in different aspects such as market size, segmentation on the basis of type of treatment, cost of treatment and import and export of anti-cancer drugs in the market. The report is useful for oncology drugs manufacturers, hospitals, government association, retail chains and new players venturing in the market.

Asia Cancer Drugs Market
The Asia oncology market has witnessed a growth in recent years on account of rising demand for anti-cancer drugs fueled by increase in healthcare expenditure, rising awareness and affordability.  The surge in growth is majorly originated from growth in Breast and Blood Cancer as a segment of cancer market. The growth is Asia oncology drug market is fueled by growth in markets of India, China and Japan. The growth in these countries has been largely led by the domestic factors such as supportive government policies, increasing demand and entry of new player in oncology drug market. The Asia Oncology drug market is comprised of large companies such as Roche which posses a large product portfolio of oncology drugs. The Asia oncology drug market revenues have grown at a CAGR of 4.3% from 2009-2014.

According to the research report, the Asia oncology drug market will grow at a considerable CAGR and will exceed over USD 20 billion by 2017 due to the increasing number of players, rising incidence of cancer and increasing demand for the oncology drugs

“Boom in ageing population in China and Japan, rising intake of health insurance and an increase in the out of pocket healthcare expenditure will result in increased revenue of oncology drug market in the Asia, volatility in global product prices, enhancing competition and development of generic drugs are few of the major challenges which will affect the growth of this industry in the future”, according to the Research Analyst, Ken Research.

Key Topics Covered in the Report:
Oncology Drugs
-          Market Size by Revenue
-          Market Segmentation by
o   Therapeutic Modalities
o   Generic and Patented Drugs
o   Local Players and Global Players
-          Trends and Development
-          SWOT
-          Export and Import
-          Competition and Market Share
-          Growth Drivers
-          Future Outlook
-          Macro Economic Parameters
-           
Key Products Mentioned in the Report
-          Generic Cancer Drugs
-          Patented Cancer Drugs
-          Chemotherapy
-          Targeted Therapy
-          Hormone Therapy
-          Immuno Therapy
-          Avsatin
-          Herceptin
-          Xalkori
-          Sutent
-          Gleevec
-          Arimidex
-          Revlimid



Companies Covered in the Report
Global Players
-          Roche
-          Pfizer
-          Novartis
-          Celgene
-          GlaxoSmithKline
-          AstraZeneca
-          Eli Lily
Domestic Players-India
-          Cipla Ltd
-          Sun Pharma Pharmaceuticals Ltd
-          Dr Reddy Laboratories Ltd
-          NATCO Pharmaceuticals Ltd
-          Biocon Ltd.

Domestic Players-China
-          Jiang Su Heng Rui Medicine Co. Ltd
-          Qilu Pharmaceuticals Co. Ltd
-          Jiangsu Hansoh Pharmaceutical Co. Ltd
-          Luye Pharma Group Ltd
-          Livzon Pharmaceutical Group

Related Reports:

                            
Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249

Friday, June 12, 2015

Cancer Drugs Market - India, China and Japan Industry Future Outlook and Projection to 2019

Asia Oncology Drug Market Outlook to 2019 – Driven by Rising Demand and Intensifying Joint Ventures between Companies” provides a comprehensive analysis of the oncology drug market in Asia. The report covers various aspects such as market size of oncology drugs, segmentation on the basis of therapeutic class, types of cancer, and volume of exports and imports for oncology drugs. The report is useful for pharmaceuticals companies, retail chains, consultants, healthcare professionals and new players venturing in the market. The market is dominated by few global players including Roche, Novartis, Pfizer and others.

Asia Cancer Drugs Market
Asia Pacific Region

The Oncology drug market in the Asia, which is hugely driven by rising demand and investment level of government, registered revenues of USD ~ million in 2013. With the advent of new oncology drug manufacturers in the industry, the revenues increased by 7.6% compared to 2013 where the total revenues was USD ~ million. Each segment in the anti-cancer drug market is subject to a gamut of different factors such as prevalence rate of specific type of cancer, price cuts and number of players in the market plays an important role in determining their respective revenues.

The oncology drug market of Asia has grown at a CAGR of 4.3% from USD ~ million in’2009 to INR ~ million in 2014. In more developed markets of the Asia-Pacific region, including countries such as Japan and China, the offerings from the market players are expected to be diverse, focused mainly on customized demands. Additionally, the market is predicted to witness expansion in terms of the newer forms of drugs because of rising cancer incidence and growing awareness. The Asia-Pacific oncology drug market is expected to grow at a CAGR of 9.0% from 2015-2019 on account of increasing affluence of consumers towards healthy lifestyles and treatment of cancer in the recent years.

The Asia oncology drug market is dominated by global pharmaceuticals companies that specialize in marketing patented drugs. The market revenues of Roche from sale of anti-cancer drugs have increased noticeably from USD ~ million in 2012 to USD ~ million in 2014, making it the largest player in oncology drug space. Pfizer was the second largest player in 2014. An inclination in the death rates of cancer patients due lack of proper treatment provides a huge opportunity to pharmaceutical companies to deliver effective drugs in the market and thus contributing to higher revenue of anti-cancer drug market.

India

The Oncology drug market in India, which is driven by the development of new alternative therapies, evolving move from chemotherapy to specific cancer targeted therapy, hormone therapy has registered revenues of INR ~ million in 2013. With an entry of new oncology drug manufacturers in the industry, the revenues increased by 65.5% compared to 2013 where the total revenues was INR ~ million. A major factor that has contributed to such a stupendous growth of this market is advances in technologies. Owing to the advancement in technology, the cancer is diagnosed much frequently and thus better treatment can be provided to the patients. The oncology drug market of India has grown at a CAGR of 22.0% from over INR 12 billion in 2009 to INR ~ million in 2014. The main competitors’ in India oncology space includes Cipla Ltd, Sun Pharma Ltd, Dr Reddy Laboratories amongst others. The India oncology drug market is expected to grow at a CAGR of 17.6% from 2015-2019 due to greater influx of patients in cancer care centers due to rising awareness among the people about the right place for best treatment will continue to escalate the growth of oncology treatment in India.

China

Additionally, China has witnessed continuous and substantial rise in the incidence as well as death caused by cancer. This rapid rise has be attributed to factors such as changing lifestyles and dietary patterns, increasing consumption of tobacco, heavy smoking and several other proximate causes. The revenue of oncology market in China increased by 15.0% compared to 2013. The market has grown at a CAGR of 17.3% from USD ~ million in 2009 to USD ~ million in 2014. The market for oncology drugs in China is dominated by local players such as Jiang Su Heng Rui Medicine Co. Ltd, Qilu Pharmaceuticals Co. Ltd and others. The China oncology drug has been anticipated to incline to about USD 30 billion in 2019 from USD ~ billion in 2014. In addition, the share of generic drugs in China Oncology market is expected to rise by a small percentage to around 72% in the year 2019.

The market for oncology drugs in Asia is changing at a rapid rate. Furthermore, new upcoming drugs, investment by government on Healthcare as well as competitive pressures have been significantly changing the market. Revenues from the anti-cancer drug market in the Asia are expected to expand to USD ~ million in 2019 growing with a CAGR of ~% from 2014-2019.

Key Topics Covered in the Report:

  • The market size of the oncology drug market in Asia
  • The market size of the generic and patented drugs in Asia oncology drug market.
  • The market size of the local and global players market Asia oncology drug market.
  • The market size of the India oncology and China oncology drug market.
  • Market segmentation of the oncology market on the basis of type of cancer, by generic and patented drugs.
  • SWOT and Porter Five force Analysis of India and China Oncology Drug market.
  • Trends and Development in the Asia oncology drug market.
  • Government Regulations in the India and China oncology drug market.
  • Competitive landscape detailed company profiles and market share of the major manufacturers of oncology drugs in Asia as well as India, China and others
  • Macro Economic factors affecting India and China Oncology drug market.
  • Future outlook and projections of Asia Oncology drug market on the basis of – geography.


Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249

Thursday, June 11, 2015

India Third Party Logistics Industry Size and Segmentation 2019 - Ken Research Report

India Logistics and Warehousing Industry Outlook to 2019 – Driven by E-commerce Logistics and Make in India initiative provides detailed overview on logistics and warehousing market in India along with their segments such as Express Logistics, 3PL Market, E-commerce Logistics, Freight Forwarding Market, Industrial and Agricultural Warehousing, Cold Chain and CFS/ICD. The report covers various aspects such as market size, value chain, business model of Logistics and Warehousing industry and segmentation on the basis of modal mix and services mix, organized and unorganized, domestic and international flow corridors. The publication also provides a detailed competitive landscape as well as the market share analysis in each segment along with future opportunities and expected catalysts for the market. The report will help industry consultants, potential entrants, logistics and warehousing companies, 3PL vendors and other stakeholders to align their market centric strategies according to ongoing and expected trends in the future.



The logistics and warehousing industry’s revenue is anticipated to grow at a CAGR of ~% during 2015-2019. 3PL, e-commerce logistics and cold chain are the 3 biggest segments in the logistics and warehousing industry in India based on future growth rates. The pressing need for time-sensitive delivery has reshaped the logistics industry as many traditional logistics players are now diversifying their services portfolio to make space for e-commerce logistics. Based on the rise of QSR market in India, cold chain market is also witnessing remarkable growth. The increased foreign trade has led to the CFS/ICD segment of warehousing industry to record impressive growth rates in the recent years and is expected to continue the same for the forthcoming years.


Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-901537824